A Phase 2, Randomized, Double-Blind, Placebo- Controlled Study of Chemo-Immunotherapy Combination using Motolimod with Pegylated Liposomal Doxorubicin in Recurrent Or Persistent Ovarian Cancer: A Gynecologic Oncology Group Partners Study

dc.contributor.authorMonk, B. J.en_US
dc.contributor.authorBrady, M. F.en_US
dc.contributor.authorAghajanian, C.en_US
dc.contributor.authorLankes, H. A.en_US
dc.contributor.authorRizack, T.en_US
dc.contributor.authorLeach, J.en_US
dc.contributor.authorFowler, J. M.en_US
dc.contributor.authorHiggins, R.en_US
dc.contributor.authorHanjani, P.en_US
dc.contributor.authorMorgan, M.en_US
dc.contributor.authorEdwards, R.en_US
dc.contributor.authorBradley, W.en_US
dc.contributor.authorKolevska, T.en_US
dc.contributor.authorFoukas, P.en_US
dc.contributor.authorSwisher, E. M.en_US
dc.contributor.authorAnderson, K. S.en_US
dc.contributor.authorGottardo, R.en_US
dc.contributor.authorBryan, J. K.en_US
dc.contributor.authorNewkirk, M.en_US
dc.contributor.authorManjarrez, K. L.en_US
dc.contributor.authorMannel, R. S.en_US
dc.contributor.authorHershberg, R. M.en_US
dc.contributor.authorCoukos, G.en_US
dc.contributor.cuauthorMonk, Bradley J.en_US
dc.date.accessioned2017-05-26T18:23:55Z
dc.date.available2017-05-26T18:23:55Z
dc.date.issued2017en_US
dc.date.monthMay 1en_US
dc.date.year2017en_US
dc.description.issue5en_US
dc.description.pages996-1004en_US
dc.description.volume28en_US
dc.identifier.citationMonk, B. J.; Brady, M. F.; Aghajanian, C.; Lankes, H. A.; Rizack, T.; Leach, J., et al. (2017). A Phase 2, Randomized, Double-Blind, Placebo- Controlled Study of Chemo-Immunotherapy Combination using Motolimod with Pegylated Liposomal Doxorubicin in Recurrent Or Persistent Ovarian Cancer: A Gynecologic Oncology Group Partners Study. Ann Oncol, May 1 2017, 28(5):996-1004. doi: http://dx.doi.org/10.1093/annonc/mdx049en_US
dc.identifier.issn1569-8041en_US
dc.identifier.issn0923-7534en_US
dc.identifier.pmid28453702en_US
dc.identifier.urihttp://hdl.handle.net/10504/113208
dc.program.unitSchool of Medicineen_US
dc.program.unitObstetrics and Gynecologyen_US
dc.program.unitPhoenix Campus (Medicine)en_US
dc.titleA Phase 2, Randomized, Double-Blind, Placebo- Controlled Study of Chemo-Immunotherapy Combination using Motolimod with Pegylated Liposomal Doxorubicin in Recurrent Or Persistent Ovarian Cancer: A Gynecologic Oncology Group Partners Studyen_US
dc.title.workAnnals of Oncologyen_US
dc.typeJournal Articleen_US
dc.url.link1http://doi.org/10.1093/annonc/mdx049en_US
Files